Kamada (KMDA) to Announce Quarterly Earnings on Wednesday

Kamada (NASDAQ:KMDA) is expected to announce its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Kamada to post earnings of $0.12 per share and revenue of $50.8390 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 11:14 AM ET.

Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.05). Kamada had a net margin of 11.21% and a return on equity of 7.73%. The company had revenue of $45.24 million for the quarter, compared to the consensus estimate of $46.72 million. On average, analysts expect Kamada to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kamada Stock Performance

KMDA stock opened at $7.34 on Wednesday. Kamada has a one year low of $6.50 and a one year high of $9.35. The company’s fifty day moving average price is $7.29 and its 200-day moving average price is $8.01. The company has a market capitalization of $422.12 million, a PE ratio of 20.97, a price-to-earnings-growth ratio of 0.66 and a beta of 0.86.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of KMDA. Jane Street Group LLC purchased a new position in shares of Kamada in the first quarter valued at $582,000. Goldman Sachs Group Inc. purchased a new stake in Kamada during the first quarter valued at $497,000. Arrowstreet Capital Limited Partnership purchased a new stake in Kamada during the second quarter valued at $472,000. Bank of America Corp DE lifted its position in Kamada by 201.0% during the third quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock valued at $427,000 after purchasing an additional 41,111 shares during the last quarter. Finally, Marshall Wace LLP lifted its position in Kamada by 25.9% during the fourth quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company’s stock valued at $1,390,000 after purchasing an additional 40,514 shares during the last quarter. 20.38% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on KMDA shares. William Blair set a $15.00 target price on shares of Kamada in a research note on Tuesday, July 21st. Wall Street Zen cut shares of Kamada from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings downgraded shares of Kamada from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 25th. Finally, Benchmark restated a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Kamada has an average rating of “Buy” and an average target price of $13.00.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.